A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered for twelve weeks either in a once-daily regimen in the morning (160 micrograms qd AM) or in a twice daily regimen (80 micrograms bid) in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids
Latest Information Update: 15 Jul 2009
At a glance
- Drugs Ciclesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jul 2009 Actual patient number changed from 446 to 456 as reported by ClinicalTrials.gov.
- 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
- 22 Sep 2006 Status change